• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性血管疾病患者的饮食摄入与心血管结局:来自 COMPASS 试验队列的观察。

Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: insights from the COMPASS trial cohort.

机构信息

Department of Medicine, Faculty of Health Sciences, McMaster University, 1280 Main St W., Hamilton L8S 4K1, Canada.

Hamilton Health Sciences, Population Health Research Institute, 237 Barton St. East, Hamilton, ON L8L 2X2, Canada.

出版信息

Eur J Prev Cardiol. 2023 Jun 1;30(8):709-718. doi: 10.1093/eurjpc/zwad062.

DOI:10.1093/eurjpc/zwad062
PMID:37080912
Abstract

AIMS

Patients with coronary artery disease (CAD) and patients with peripheral artery disease (PAD) are at risk for major adverse cardiovascular events (MACE) and major adverse limb events (MALE). There are limited data regarding dietary patterns and the risk of recurrent MACE and MALE in CAD and PAD patients. We aimed to identify dietary patterns associated with MACE and MALE in patients with CAD and/or PAD.

METHODS AND RESULTS

We analysed data collected from patients enrolled into the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial, in which diet was assessed by a short food frequency questionnaire (FFQ) at baseline. Two dietary pattern scores, the modified Alternate Healthy Eating Index (mAHEI) and Mediterranean Diet Score (mMDS), were calculated. We tested the association between mAHEI and mMDS and the incidence of MACE and/or MALE. The mean mAHEI score was 23.0 ± 7.7 (out of 70) overall and was similar comparing CAD and PAD patients. The incidence of MACE or MALE was 6.3% in the lowest diet quality quartile (as assessed by mAHEI) compared with 4.2% in the highest quartile over 30 months. In the fully adjusted model, the hazard ratio of a low diet quality (Quartile 1) compared with the highest (Quartile 4) for MACE or MALE was 1.27 (95% CI: 1.08-1.49; P = 0.004, Q1 vs. Q4). This excess hazard was primarily driven by higher MACE in both the CAD and PAD cohorts.

CONCLUSIONS

Poor diet quality as assessed by the mAHEI is independently associated with a higher risk of recurrent MACE and MALE in patients with chronic CAD and/or PAD.

摘要

目的

患有冠状动脉疾病(CAD)和外周动脉疾病(PAD)的患者有发生主要不良心血管事件(MACE)和主要不良肢体事件(MALE)的风险。关于饮食模式与 CAD 和 PAD 患者复发性 MACE 和 MALE 风险之间的关系,数据有限。我们旨在确定与 CAD 和/或 PAD 患者的 MACE 和 MALE 相关的饮食模式。

方法和结果

我们分析了参加抗凝策略在心血管结局中的应用(COMPASS)试验的患者的数据,该试验在基线时通过简短的食物频率问卷(FFQ)评估饮食。计算了两种饮食模式评分,改良交替健康饮食指数(mAHEI)和地中海饮食评分(mMDS)。我们测试了 mAHEI 和 mMDS 与 MACE 和/或 MALE 发生率之间的关联。总体而言,mAHEI 的平均得分是 23.0±7.7(满分 70 分),CAD 和 PAD 患者的得分相似。在 30 个月的时间里,最低饮食质量四分位数(mAHEI 评估)的 MACE 或 MALE 发生率为 6.3%,而最高四分位数为 4.2%。在完全调整的模型中,低饮食质量(四分位数 1)与最高饮食质量(四分位数 4)相比,MACE 或 MALE 的风险比为 1.27(95%CI:1.08-1.49;P=0.004,Q1 比 Q4)。这种额外的风险主要是由于 CAD 和 PAD 两个队列中 MACE 发生率更高所致。

结论

用 mAHEI 评估的饮食质量差与慢性 CAD 和/或 PAD 患者复发性 MACE 和 MALE 的风险增加独立相关。

相似文献

1
Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: insights from the COMPASS trial cohort.慢性血管疾病患者的饮食摄入与心血管结局:来自 COMPASS 试验队列的观察。
Eur J Prev Cardiol. 2023 Jun 1;30(8):709-718. doi: 10.1093/eurjpc/zwad062.
2
Incidence and Cost of Major Adverse Cardiovascular Events and Major Adverse Limb Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease.慢性冠状动脉疾病或外周动脉疾病患者的主要不良心血管事件和主要不良肢体事件的发生率和成本。
Am J Cardiol. 2019 Jun 15;123(12):1893-1899. doi: 10.1016/j.amjcard.2019.03.022. Epub 2019 Mar 16.
3
Health status and cognitive function for risk stratification in chronic coronary and peripheral artery disease.慢性冠状动脉和外周动脉疾病的风险分层的健康状况和认知功能。
Eur J Prev Cardiol. 2023 May 9;30(7):535-545. doi: 10.1093/eurjpc/zwac282.
4
Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial.沃拉帕沙对伴有和不伴有冠状动脉疾病的外周动脉疾病患者心血管和肢体结局的影响:来自 TRA 2°P-TIMI 50 试验的分析。
Vasc Med. 2020 Apr;25(2):124-132. doi: 10.1177/1358863X19892690. Epub 2020 Jan 30.
5
Real-World Predictors of Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients with Chronic Coronary Artery Disease and/or Peripheral Arterial Disease.慢性冠状动脉疾病和/或外周动脉疾病患者主要不良心血管事件和主要不良肢体事件的真实世界预测因素。
Adv Ther. 2020 Jan;37(1):240-252. doi: 10.1007/s12325-019-01132-z. Epub 2019 Nov 8.
6
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.替卡格雷与氯吡格雷在有症状外周动脉疾病和既往冠状动脉疾病患者中的比较:来自 EUCLID 试验的结果。
Vasc Med. 2018 Dec;23(6):523-530. doi: 10.1177/1358863X18775594. Epub 2018 Jul 11.
7
Effect of Cerebrovascular and/or Peripheral Artery Disease With or Without Attainment of Lipid Goals on Long-Term Outcomes in Patients With Coronary Artery Disease.脑血管病和/或外周动脉疾病患者降脂目标达标与未达标对冠状动脉疾病患者长期预后的影响。
Am J Cardiol. 2020 Aug 1;128:28-34. doi: 10.1016/j.amjcard.2020.04.043. Epub 2020 May 13.
8
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.主要肢体不良事件和外周动脉疾病患者的死亡率:COMPASS 试验。
J Am Coll Cardiol. 2018 May 22;71(20):2306-2315. doi: 10.1016/j.jacc.2018.03.008. Epub 2018 Mar 11.
9
Impact of preexisting coronary artery and peripheral artery disease on outcomes in diabetic patients after kidney transplant.糖尿病患者肾移植术后预先存在的冠状动脉和外周动脉疾病对结局的影响。
Vasc Med. 2024 Apr;29(2):135-142. doi: 10.1177/1358863X231205574. Epub 2023 Nov 7.
10
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.利伐沙班与阿司匹林用于有症状的下肢外周动脉疾病患者:COMPASS随机临床试验的亚组分析
JAMA Cardiol. 2021 Jan 1;6(1):21-29. doi: 10.1001/jamacardio.2020.4390.

引用本文的文献

1
Peripheral artery disease.外周动脉疾病
Nat Rev Dis Primers. 2025 Sep 18;11(1):68. doi: 10.1038/s41572-025-00651-0.
2
[What is new in the management of peripheral arterial occlusive disease and diseases of the aorta? : Highlights of the ESC guidelines 2024].[外周动脉闭塞性疾病和主动脉疾病管理的新进展是什么?:2024年欧洲心脏病学会指南要点]
Herz. 2025 Feb;50(1):25-33. doi: 10.1007/s00059-024-05286-7. Epub 2024 Nov 26.
3
Healthy Diets and Lifestyles in the World: Mediterranean and Blue Zone People Live Longer. Special Focus on Gut Microbiota and Some Food Components.
世界上的健康饮食和生活方式:地中海和蓝区人群寿命更长。特别关注肠道微生物群和一些食物成分。
Endocr Metab Immune Disord Drug Targets. 2024;24(15):1774-1784. doi: 10.2174/0118715303271634240319054728.
4
Exercise Training for Patients With Peripheral Arterial Occlusive Disease.外周动脉闭塞性疾病患者的运动训练
Dtsch Arztebl Int. 2023 Dec 27;120(51-52):879-885. doi: 10.3238/arztebl.m2023.0231.